Fresh analysis suggests that people who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who halt traditional lifestyle regimens.
Research printed in a major health publication points out that while overweight people can lose substantial amounts of their body weight while on the medication, the weight returns at an estimated rate of nearly a kilo each month after stopping.
"Users purchasing these medications need to be aware of the potential of quick rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a return to starting weight within about a year and a half.
Comparing Approaches
The research, which examined dozens of trials involving thousands of patients, compared the results of the injectable medications with older methods.
The team point out that people who lose weight through dieting typically experience a slower creep back—perhaps 100 grams monthly—once they finish.
The Reason for the Quick Regain
Experts believe the mode of action of the jabs explains the amplified regain.
The injections mimic a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of the hormone levels several times higher than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement means hunger is uncontrolled, making excessive eating far more likely."
A Lifelong Issue?
Medical guidelines suggest the jabs for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts argue that, given the likelihood of relapse, the therapy should be considered ongoing.
This view is reinforced by drug manufacturers, who note that the findings "underscore the long-term character of excess weight," akin to managing conditions like high blood pressure.
User Testimonies
People who have discontinued the medication report a intense resurgence of appetite.
"It felt as if a trigger flipping and I was suddenly starving," recalled one woman.
The struggle is compounded if users have not established sustainable lifestyle or habit changes during therapy.
Significant Use
Figures indicate that millions of adults in the UK have used these injections in the past year, with demand continuing to grow.
- Use is higher among women compared to males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, clinicians caution that while these medications are potent agents for weight loss, they are not a permanent fix and lasting health benefits hinges on ongoing behavioural changes.
